<DOC>
	<DOCNO>NCT02515279</DOCNO>
	<brief_summary>This noninterventional , open-label study observe safety tolerability peginterferon alfa-2a combination ribavirin among Austrian participant treat HCV infection accord routine practice .</brief_summary>
	<brief_title>An Observational Study Peginterferon Alfa-2a Plus Ribavirin Hepatitis C Virus ( HCV ) Infection Austria</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Ongoing treatment peginterferon alfa2a ribavirin discretion prescribe physician HCV infection None specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>